Intellectual Property In Marine-Derived Bioactive Compounds – Detailed Explanation With Case Laws

1. Introduction

Intellectual Property (IP) in Marine-Derived Bioactive Compounds refers to the legal protection of innovative products, chemical substances, biological materials, pharmaceutical compounds and technologies developed from marine organisms.

Marine organisms such as algae, seaweeds, sponges, corals, marine bacteria, fungi and molluscs contain unique bioactive compounds with pharmaceutical, agricultural, cosmetic and industrial applications.

These compounds may possess antibacterial, antiviral, anticancer, antifungal, anti-inflammatory and antioxidant properties.

Examples include:

Trabectedin: An anticancer compound originally identified from a marine sea squirt.

Eribulin: A synthetic anticancer drug developed from a marine natural product.

Cytarabine: A medicine inspired by nucleosides discovered in marine sponges.

Marine-derived enzymes: Used in biotechnology and industrial processing.

Marine algal compounds: Used in pharmaceutical and cosmetic products.

Intellectual property law encourages investment in marine biotechnology while ensuring that biological resources are not exploited unfairly.

2. Meaning of Intellectual Property in Marine-Derived Bioactive Compounds

Marine-derived bioactive compounds are naturally occurring or scientifically modified substances obtained from marine organisms that demonstrate biological activity.

Intellectual property protection may apply to:

Newly developed pharmaceutical compounds.

Chemically modified marine natural products.

Synthetic versions of marine-derived molecules.

Novel extraction and purification techniques.

Genetically engineered marine microorganisms.

Marine biotechnology manufacturing processes.

Pharmaceutical formulations containing marine compounds.

Industrial applications of marine-derived enzymes.

However, discovering a naturally occurring marine compound does not automatically create an intellectual property right.

3. Legal Framework Governing Intellectual Property

A. TRIPS Agreement

The Agreement on Trade-Related Aspects of Intellectual Property Rights establishes minimum international standards for intellectual property protection.

Article 27 provides that patents should generally be available for inventions in all fields of technology, subject to novelty, inventive step and industrial applicability.

It is relevant to marine-derived pharmaceutical inventions, genetically modified microorganisms, marine enzymes and synthetic bioactive compounds.

B. Convention on Biological Diversity, 1992

The Convention on Biological Diversity establishes three major objectives:

Conservation of biological diversity.

Sustainable use of biological resources.

Fair and equitable sharing of benefits arising from genetic resources.

It recognizes the sovereign rights of states over their natural resources.

C. Nagoya Protocol, 2010

The Nagoya Protocol establishes an international framework for access to genetic resources and benefit-sharing.

Its important principles include:

Prior informed consent.

Mutually agreed terms.

Fair benefit-sharing.

Recognition of traditional knowledge.

Compliance with domestic access laws.

D. United Nations Convention on the Law of the Sea

UNCLOS provides the international legal framework for marine resources, scientific research and environmental protection.

It is relevant to the collection and use of marine organisms for biotechnology research.

E. BBNJ Agreement, 2023

The Agreement on Marine Biological Diversity of Areas Beyond National Jurisdiction was adopted in 2023 and entered into force on 17 January 2026.

It addresses marine genetic resources and digital sequence information from areas beyond national jurisdiction.

Its framework includes notification, information-sharing, benefit-sharing, capacity-building and technology transfer.

4. Types of Intellectual Property Protection

A. Patent Protection

Patents are among the most important forms of intellectual property protection for marine-derived bioactive compounds.

A patent may protect:

Novel chemically modified marine compounds.

Synthetic analogues.

Pharmaceutical formulations.

New extraction techniques.

Genetically engineered marine microorganisms.

Novel manufacturing methods.

The invention must satisfy the applicable requirements of novelty, inventive step and industrial applicability.

B. Trade Secret Protection

Trade secrets protect confidential commercial and technical information.

Examples include:

Extraction procedures.

Fermentation techniques.

Purification methods.

Production conditions.

Manufacturing formulations.

C. Copyright Protection

Copyright may protect original scientific publications, laboratory manuals, databases, software, scientific illustrations and research reports.

It protects the expression of scientific information rather than the underlying natural compound.

D. Industrial Design Protection

Industrial design protection may apply to the visual appearance of pharmaceutical packaging, cosmetic containers and biotechnology equipment.

E. Trademark Protection

Trademarks protect the commercial identity of medicines, cosmetics and nutraceutical products containing marine-derived ingredients.

5. Patentability Requirements

A. Novelty

The invention must be new and must not form part of the prior art.

A previously known natural compound does not become patentable merely because a researcher independently isolates it.

B. Inventive Step

The invention must not be obvious to a person skilled in the relevant technical field.

For example, a chemically modified marine compound demonstrating an unexpected improvement in anticancer activity may qualify.

C. Industrial Applicability

The invention must be capable of practical industrial application.

D. Sufficient Disclosure

The patent application must disclose the invention sufficiently clearly to enable a skilled person to perform it.

E. Biological Material Disclosure

Where an invention involves biological material that cannot adequately be described in writing, applicable patent laws may require deposit of the material in a recognized depositary institution.

6. Major Intellectual Property Challenges

A. Ownership of Naturally Occurring Marine Compounds

One major challenge is determining who can legally claim ownership over compounds discovered in marine organisms.

Marine resources may originate from territorial waters, Exclusive Economic Zones, continental shelves or international waters.

Patent ownership and ownership or control of the original biological resource are legally distinct matters.

B. Biopiracy

Biopiracy refers to unauthorized acquisition or commercial exploitation of biological resources or associated traditional knowledge without appropriate authorization or benefit-sharing.

It can create disputes concerning resource ownership, patent validity, access permissions and environmental justice.

C. Disclosure of Origin

Patent applicants may face disclosure requirements concerning the source or geographical origin of biological resources.

These requirements differ between jurisdictions.

D. Digital Sequence Information

Modern biotechnology uses digital sequence information rather than only physical biological samples.

This creates questions concerning ownership, commercial use, access and benefit-sharing.

E. Environmental Protection

Commercial collection of marine organisms can threaten biodiversity and sensitive ecosystems.

Therefore, intellectual property protection must operate alongside environmental conservation requirements.

F. Research and Development Costs

Marine biotechnology research involves deep-sea exploration, sample collection, laboratory testing, chemical characterization, clinical trials and pharmaceutical manufacturing.

Patent protection may encourage investment in these activities.

7. Important Case Laws

Case 1: Diamond v. Chakrabarty (1980)

Citation: 447 U.S. 303 (1980), United States Supreme Court.

Facts:
The case concerned a genetically engineered bacterium developed by Ananda Chakrabarty that could break down multiple components of crude oil.

Legal Issue:
Whether a genetically modified living microorganism could qualify as patentable subject matter.

Judgment:
The United States Supreme Court held that a genetically engineered microorganism could be patented because it was a human-made invention rather than merely a naturally occurring organism.

Legal Principle:
Human-made biological inventions may qualify for patent protection when they possess characteristics significantly different from those found in nature.

Relevance:
This judgment is relevant to genetically engineered marine bacteria and microorganisms developed for producing pharmaceutical compounds and industrial enzymes.

Case 2: Funk Brothers Seed Co. v. Kalo Inoculant Co. (1948)

Citation: 333 U.S. 127 (1948), United States Supreme Court.

Facts:
The case involved a mixture of different strains of nitrogen-fixing bacteria used in agricultural inoculants.

Legal Issue:
Whether the discovery of naturally occurring characteristics of microorganisms could justify patent protection.

Judgment:
The Supreme Court held that the claimed combination was not patentable because the inventor had merely discovered natural properties of existing bacteria without producing a sufficiently inventive application.

Legal Principle:
A discovery of natural biological characteristics is not automatically patentable.

Relevance:
Simply discovering that a marine microorganism produces an antibacterial substance may not be sufficient to establish patentability.

Case 3: Association for Molecular Pathology v. Myriad Genetics, Inc. (2013)

Citation: 569 U.S. 576 (2013), United States Supreme Court.

Facts:
Myriad Genetics identified the location and sequence of BRCA1 and BRCA2 genes and obtained patents relating to isolated DNA.

Legal Issue:
Whether naturally occurring genetic material could become patentable merely through isolation.

Judgment:
The Supreme Court held that naturally occurring DNA segments were not patentable merely because they had been isolated. However, synthetically created complementary DNA could be patentable in certain circumstances.

Legal Principle:
The discovery and isolation of a natural biological substance do not automatically transform it into a patentable invention.

Relevance:
This judgment is important for marine genetic resources and naturally occurring genetic sequences extracted from marine organisms.

Case 4: Mayo Collaborative Services v. Prometheus Laboratories, Inc. (2012)

Citation: 566 U.S. 66 (2012), United States Supreme Court.

Facts:
The case concerned patent claims involving methods for determining appropriate drug dosages based on metabolite levels in a patient's blood.

Legal Issue:
Whether a patent could claim naturally occurring biological relationships without adding sufficient inventive features.

Judgment:
The Supreme Court held that the claims were directed to natural laws and did not contain sufficient additional inventive elements.

Legal Principle:
Natural laws and biological relationships cannot be monopolized merely by adding conventional or routine steps.

Relevance:
This principle is relevant to patent applications involving natural biochemical properties of marine-derived compounds.

Case 5: Harvard College v. Canada (Commissioner of Patents) (2002)

Citation: 2002 SCC 76, Supreme Court of Canada.

Facts:
Harvard College sought patent protection for a genetically modified mouse developed for cancer research, commonly known as the Oncomouse.

Legal Issue:
Whether a genetically modified higher life form constituted a patentable invention under Canadian patent legislation.

Judgment:
The Supreme Court of Canada held that higher life forms, as claimed in the patent application, were not patentable subject matter under the relevant statutory language.

Legal Principle:
Patent eligibility of biological inventions depends on the wording and interpretation of applicable national patent legislation.

Relevance:
This judgment demonstrates that patentability of marine organisms and biological inventions may differ across jurisdictions.

Case 6: Dimminaco A.G. v. Controller of Patents and Designs (2002)

Citation: 2002 (24) PTC 193 (Cal), Calcutta High Court, India.

Facts:
Dimminaco A.G. applied for a patent relating to a process for preparing a live vaccine against infectious bursal disease in poultry.

Legal Issue:
Whether a manufacturing process resulting in a living end product could qualify for patent protection.

Judgment:
The Calcutta High Court held that a process should not be rejected merely because its end product is a living substance.

Legal Principle:
A process resulting in a living product may be patentable if it otherwise satisfies the legal requirements.

Relevance:
This decision is relevant to processes involving marine microorganisms, fermentation systems and biological production of marine-derived pharmaceutical substances.

Case 7: Divya Pharmacy v. Union of India (2018)

Citation: Writ Petition (M/S) No. 3437 of 2016, Uttarakhand High Court.

Facts:
The dispute concerned benefit-sharing obligations imposed on commercial users of biological resources under India's Biological Diversity Act, 2002.

Legal Issue:
Whether biodiversity authorities could impose benefit-sharing obligations on commercial users of biological resources.

Judgment:
The Uttarakhand High Court upheld the National Biodiversity Authority's regulatory authority to require benefit-sharing in accordance with the applicable biodiversity legislation.

Legal Principle:
Commercial utilization of biological resources must respect applicable biodiversity and benefit-sharing obligations.

Relevance:
This decision is significant for companies using marine organisms obtained from Indian biological resources.

8. Intellectual Property Protection in India

A. Patents Act, 1970

The Indian Patents Act provides the primary framework for patent protection.

Important provisions include:

Section 2(1)(j): Definition of invention.

Section 3(c): Exclusion of mere discoveries of scientific principles and naturally occurring substances.

Section 3(d): Restrictions concerning certain new forms of known substances.

Section 3(j): Exclusion relating to plants and animals, subject to the statutory exceptions.

Section 10: Requirements concerning patent specifications and disclosure.

B. Biological Diversity Act, 2002

The Biological Diversity Act regulates access to India's biological resources and associated traditional knowledge.

Important provisions include:

Section 3: Regulation of access by specified foreign persons and entities.

Section 4: Regulation of transfer of research results.

Section 6: Regulation of intellectual property applications based on biological resources.

Section 7: Regulation of access by certain Indian persons and entities.

Section 21: Fair and equitable benefit-sharing.

The applicable requirements must be considered in light of the 2023 amendments.

C. National Biodiversity Authority

The National Biodiversity Authority plays an important role in implementing India's biodiversity legislation.

Its responsibilities include:

Regulating access to biological resources in applicable circumstances.

Considering relevant intellectual property applications.

Facilitating benefit-sharing arrangements.

Protecting biological resources and associated traditional knowledge.

Promoting sustainable utilization of biodiversity.

9. Role of Intellectual Property in Pharmaceutical Development

Marine-derived bioactive compounds have significant pharmaceutical potential.

Intellectual property protection encourages investment in:

Anticancer drug development.

Antiviral drug discovery.

Antibiotic research.

Immunomodulatory therapies.

Anti-inflammatory medicines.

Novel drug delivery systems.

For example, trabectedin originated from research on a marine organism and became an important anticancer pharmaceutical.

Patent protection may encourage investment in chemical synthesis, clinical development, manufacturing and regulatory approval.

10. Benefit-Sharing and Ethical Considerations

Marine biotechnology raises important ethical and economic questions concerning the fair distribution of commercial benefits.

Possible benefit-sharing arrangements include:

Monetary payments.

Research funding.

Technology transfer.

Scientific training.

Joint research programmes.

Sharing of research results.

Local manufacturing opportunities.

Institutional collaboration.

Fair benefit-sharing is important when commercial products are developed using biological resources obtained from another country.

11. Emerging Issues

A. Artificial Intelligence in Marine Drug Discovery

Artificial intelligence is increasingly used to identify useful compounds from marine organisms by analysing chemical structures, genetic sequences and biological activity.

This raises questions concerning inventorship, ownership and patent eligibility.

B. Synthetic Biology

Synthetic biology allows researchers to modify microorganisms to produce marine-derived compounds without repeatedly harvesting natural marine organisms.

C. Deep-Sea Bioprospecting

Deep-sea ecosystems contain microorganisms and organisms with unique biochemical characteristics.

Their commercial exploitation raises questions concerning international jurisdiction, resource access and benefit-sharing.

D. Digital Sequence Information

Digital genetic information allows companies to develop inventions without physically collecting marine organisms.

This creates challenges concerning access rules, benefit-sharing and patent systems.

E. Sustainable Marine Biotechnology

Future intellectual property systems must encourage innovations that reduce environmental damage and support sustainable manufacturing.

12. Critical Analysis

Intellectual property protection in marine-derived bioactive compounds represents an important intersection between biotechnology, patent law, biodiversity conservation and international trade.

Patents encourage pharmaceutical research by providing commercial incentives for developing new medicines and industrial products.

However, excessive patent monopolies over biological discoveries may restrict scientific research and create unequal access to marine genetic resources.

The Convention on Biological Diversity, Nagoya Protocol and BBNJ Agreement seek to address these concerns through access regulation, benefit-sharing and international cooperation.

A balanced legal approach should:

Protect genuinely innovative marine biotechnology inventions.

Prevent monopolization of naturally occurring biological substances.

Promote transparent disclosure of biological resource origins.

Ensure compliance with access and benefit-sharing requirements.

Encourage sustainable marine resource utilization.

Protect legitimate scientific research.

Promote technology transfer and international cooperation.

13. Conclusion

Intellectual Property in Marine-Derived Bioactive Compounds is an important area of modern biotechnology law.

Marine organisms provide valuable sources of pharmaceutical, agricultural, industrial and cosmetic innovations.

Patent protection encourages researchers and pharmaceutical companies to invest in identifying, modifying, synthesizing and commercializing marine-derived compounds.

However, the discovery of a naturally occurring marine substance does not automatically establish patent ownership. Patent protection generally requires a qualifying invention that satisfies novelty, inventive step and industrial applicability.

Judicial decisions such as Diamond v. Chakrabarty, Funk Brothers v. Kalo Inoculant, Myriad Genetics, Mayo v. Prometheus, Harvard College v. Canada, Dimminaco v. Controller of Patents and Divya Pharmacy v. Union of India provide important legal principles governing biological inventions, natural substances and benefit-sharing.

In India, the Patents Act, 1970 and Biological Diversity Act, 2002 provide essential safeguards for protecting innovation while regulating the utilization of biological resources.

Ultimately, an effective intellectual property framework must maintain a balance between scientific innovation, commercial interests, environmental sustainability and the fair distribution of benefits arising from marine biodiversity.

14. Important Case Laws – Quick Revision

Diamond v. Chakrabarty (1980) – Patentability of human-made microorganisms.

Funk Brothers v. Kalo (1948) – Natural biological properties are not independently patentable.

Myriad Genetics (2013) – Mere isolation of naturally occurring DNA is insufficient.

Mayo v. Prometheus (2012) – Natural laws and biological relationships cannot be monopolized.

Harvard College v. Canada (2002) – Patentability limitations concerning higher life forms.

Dimminaco v. Controller of Patents (2002) – Processes producing living products may be patentable.

Divya Pharmacy v. Union of India (2018) – Benefit-sharing obligations relating to biological resources.

15. Important Legal Provisions – Quick Revision

TRIPS Agreement – Articles 27 and 28.

Convention on Biological Diversity – Articles 3, 15 and 16.

Nagoya Protocol – Articles 5, 6 and 7.

BBNJ Agreement – Article 12 and benefit-sharing framework.

Indian Patents Act, 1970 – Sections 2, 3 and 10.

Biological Diversity Act, 2002 – Sections 3, 4, 6, 7 and 21.

UNCLOS, 1982 – Marine scientific research and marine environmental protection provisions.

Overall Legal Principle: Marine-derived bioactive compounds may receive intellectual property protection when they satisfy the requirements of patent law. However, such protection must be distinguished from ownership of the original marine biological resource and must operate consistently with applicable biodiversity, environmental and benefit-sharing obligations.